arrow_back Trending Legislation
Share share

Fairness in Orphan Drugs: Ending Exclusivity for Profitable Medicines

This act changes the rules for granting market exclusivity for drugs intended for rare diseases. It aims to prevent abuses where companies receive special privileges even if the drug is already profitable. This could lead to greater availability and potentially lower prices for orphan drugs, as more companies may be able to produce them.
Key points
Limiting market exclusivity for rare disease drugs if their production and sales are already profitable.
Pharmaceutical companies must prove they won't recover development costs from sales to gain or keep exclusivity.
Changes apply to both new and already approved drugs, potentially increasing competition and access to orphan drugs.
article Official text account_balance Process page notifications_active Track this Bill
95%
VOTING RESULTS
2021-05-19
For 402
Against 23
Abstain 0
Full voting results open_in_new
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Fairness in Orphan Drug Exclusivity Act
Print number: HR 1629
Sponsor: Rep. Dean, Madeleine [D-PA-4]
Process start date: 2021-03-08
Voting date: 2021-05-19
Meeting no: 1
Voting no: 150
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Fairness in Orphan Drugs: Ending Exclusivity for Profitable Medicines

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is HR 1629.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-03-08.

What are the main provisions?

Key points include:

  • Limiting market exclusivity for rare disease drugs if their production and sales are already profitable.
  • Pharmaceutical companies must prove they won't recover development costs from sales to gain or keep exclusivity.
  • Changes apply to both new and already approved drugs, potentially increasing competition and access to orphan drugs.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Where is the official voting record?

The official roll call vote is recorded at: voting record

Who is the primary sponsor?

The primary sponsor is Rep. Dean, Madeleine [D-PA-4].

What is the latest detailed status?

The latest detailed status is: On passage Passed by the Yeas and Nays: 402 - 23 (Roll no. 150). (text: CR H2561)

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-27.

Analysis and Potential Impact of HR 1629

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health